About the Authors

Michelle L. T. Nguyen

Contributed equally to this work with: Michelle L. T. Nguyen, Dimitre R. Simeonov

Affiliations Department of Microbiology and Immunology, University of California, San Francisco, California, United States of America, Diabetes Center, University of California, San Francisco, California, United States of America, Innovative Genomics Institute, University of California, Berkeley, California, United States of America

Dimitre R. Simeonov

Contributed equally to this work with: Michelle L. T. Nguyen, Dimitre R. Simeonov

Affiliations Department of Microbiology and Immunology, University of California, San Francisco, California, United States of America, Diabetes Center, University of California, San Francisco, California, United States of America, Innovative Genomics Institute, University of California, Berkeley, California, United States of America, Biomedical Sciences Graduate Program, University of California, San Francisco, California, United States of America

Alexander Marson

alexander.marson@ucsf.edu

Affiliations Department of Microbiology and Immunology, University of California, San Francisco, California, United States of America, Diabetes Center, University of California, San Francisco, California, United States of America, Innovative Genomics Institute, University of California, Berkeley, California, United States of America, Department of Medicine, University of California, San Francisco, California, United States of America, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, California, United States of America, Chan Zuckerberg Biohub, San Francisco, California, United States of America

Competing Interests

I have read the journal's policy and have the following conflicts: A.M. is an advisor to Juno Therapeutics and PACT Therapeutics and is a founder of Spotlight Therapeutics. The Marson lab has received sponsored research funding from Juno Therapeutics and Epinomics.